Profitelligence Profitelligence · Filing Ledger Open JNJ research →

Form 8-K · Current Report · Filed 2025-10-14

Johnson & Johnson Reports Strong Q3 2025 Results and Announces Orthopaedics Business Separation

Johnson & Johnson reported a 6.8% increase in sales for Q3 2025, reaching $24.0 billion, driven by strong performances in Oncology, Immunology, and Cardiovascular segments.

Filer
Johnson & Johnson JNJ · NYSE
Filed
Accession
0000200406-25-000201
CIK
0000200406
Signal
High impactHealthcare

Details

The company also announced its intent to separate the Orthopaedics business. The company raised its full-year sales outlook to $93.7 billion at the midpoint, reflecting a 5.7% growth.

Items reported

Item 2.02

Results of Operations and Financial Condition

Earnings Beat Raised Guidance
Item 8.01

Other Events

Corporate Update

Market reaction

Close before filing

$190.90

Next session

+0.1%

Since filing

+34.3%

Latest close

$256.35

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from JNJ reporting the same item, with the next session's move:

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another JNJ filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts